Do temperature and time matter in cold agglutinin disease?

摘要

In this issue of Blood, Berentsen and coworkers describe the clinical features of the largest data set (N = 232) of patients with confirmed cold agglutinin disease (CAD) from 24 enters in 5 countries, suggesting a climate dependence for prevalence and incidence.(1) Furthermore, the long-term followup of outcomes of rituximab-based chemotherapy regimens, especially in combination with bendamustine, reveals greater and longer-lasting responses that became deeper over time.